Jubilant Pharmova targets revenue doubling by 2030

Jubilant Pharmova aims to double revenues to Rs. 13,500 crore by FY30 from Rs. 6,703 crore in FY24, targeting EBITDA margins of 23% to 25%.

The company's Radiopharma division plans to more than double revenue by FY30, driven by Ruby-Fill and new PET/SPECT products. Its radiopharmacy network will expand from 3 to 9 sites by FY28.

CDMO Sterile Injectables will double revenues through capacity expansion in Spokane, while Drug Discovery Services targets tripling revenues by expanding in Greater Noida, Bengaluru, and a new Devanahalli site.

The Generics segment aims to double revenues focusing on profitable non-US international business. Proprietary Novel Drugs will continue investing in two lead programs, with clinical data expected by 2026.